Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma

作者：Katharine Herbert, Rosanna Upstill‐Goddard, Stephan B. Dreyer, Selma Rebus, Christian Pilarsky, Debabrata Mukhopadhyay, Christopher J. Lord, Andrew V. Biankin, Fieke E. M. Froeling, David K. Chang · 发表于：British Journal of Cancer · 年份：2025 · DOI：10.1038/s41416-025-03051-z · 被引用次数：8 · 研究领域：PARP inhibition in cancer therapy、Cell death mechanisms and regulation、DNA Repair Mechanisms

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains the most lethal cancer. While DNA damaging agents such as platinum and PARP inhibitors have derived clinical benefits, acquired resistance invariably develops. Hence there is an urgent need for novel therapeutic strategies to overcome acquired resistance. METHODS: Clinically relevant resistance in PDAC patient-derived cell lines was achieved by extended exposure to chemotherapy agents. Synergy scoring, clonogenicity, flow cytometry, immunofluorescence, and transcriptomic analysis were used to investigate the efficacy of ATR (ceralasertib) and PARP (olaparib) inhibitors in overcoming acquired resistance. RESULTS: Acquired resistance was associated with transcriptomic shifts in cell cycle checkpoint regulation, metabolic control, DNA damage response (DDR), programmed cell death, and the replication stress response. Combination treatment with ceralasertib, and olaparib was synergistic in all models of acquired resistance. Sequential use of ceralasertib prior to olaparib was highly effective at low dose for DDR proficient models, whereas DDR deficient models responded better with olaparib treatment first. CONCLUSIONS: We provide in vitro evidence of a novel therapeutic strategy to overcome acquired resistance to PARP inhibitor and platinum in PDAC, using sequential exposure to ceralasertib and olaparib. A sequential regimen should be investigated clinically to circumvent dose limiting toxicity seen in concurrent combinat...